Pipeline
Armed-T
Armed-T is a preclinical-stage immuno-oncology platform developed by SL BIO that explores the use of bispecific antibody engineering to redirect T cells toward tumor-associated antigens. Unlike CAR-T cell therapies, which involve the genetic modification of T cells to express chimeric antigen receptors, the Armed-T platform employs a CD19-targeting bispecific antibody to engage endogenous T cells without altering their genome. Current early-stage research efforts focus on evaluating the potential of Armed-T to mediate targeted immune activation in preclinical cancer models. This approach is designed to offer a non-genetic, flexible alternative to traditional T cell engineering strategies. Armed-T forms a key component of SL BIO’s next-generation immune redirection pipeline aimed at expanding therapeutic possibilities in hematologic and solid tumors.
Note: The Armed-T platform is under preclinical investigation. All referenced results are based on laboratory and animal studies. Clinical safety and efficacy have not been established.
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-AT001
B cell leukemia
SL-AT001 (B cell leukemia)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-AT001
B cell leukemia
SL-AT001 is an early-stage investigational program evaluating the Armed-T platform, which utilizes a bispecific antibody approach designed to redirect T cells toward B cell-associated markers. Unlike CAR-T therapies that require genetic modification, Armed-T employs a CD19-targeting bispecific antibody to engage T cells through a non-viral, non-genetic mechanism. The SL-AT001 program is currently undergoing preclinical evaluation in hematologic malignancy models, focusing on immune activation, tumor-associated targeting, and feasibility for scalable manufacturing. This program is part of SL BIO’s broader research effort to explore non-genetically modified immune redirection platforms for potential therapeutic applications.
Note: SL-AT001 is at the preclinical stage. The results described are based on laboratory research and animal models. Clinical safety and efficacy have not been established.